Peptides in Sport and Bodybuilding: What a New Review Says About the Risks

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Many of the substances discussed here are prohibited in competitive sport and not approved for the performance uses described. Do not use any medication, peptide, or supplement without consulting a licensed healthcare provider.

Walk through any online bodybuilding forum or fitness subreddit today and you will encounter peptides discussed with the same casual familiarity once reserved for protein shakes. Ipamorelin. CJC-1295. Sermorelin. Fragment 176-191. Marketed as cleaner, smarter, and safer than anabolic steroids, these compounds have moved from research labs into an expanding gray market — with very little longitudinal safety data following them.

A critical review published in the Journal of Sports Medicine and Physical Fitness in March 2026 examines this trend head-on. The authors — researchers at the Faculty of Medical Sciences of Minas Gerais in Brazil — synthesize what is actually known about peptide use in sport and bodybuilding, and their conclusions are more cautious than the promotional material circulating online.

The Peptides at Issue

The review focuses on several classes of performance-relevant peptides:

Growth hormone secretagogues (GHS) — compounds that stimulate the pituitary gland to release more growth hormone:

• Ipamorelin — a selective ghrelin receptor agonist known for stimulating GH release with relatively minimal cortisol or prolactin response
• CJC-1295 — a modified GHRH analogue with a long half-life due to Drug Affinity Complex technology
• Sermorelin — an analogue of the first 29 amino acids of GHRH; FDA-approved for GH deficiency in children but used off-label by adults

Growth hormone fragments:

• Fragment 176-191 — the C-terminal fragment of growth hormone, marketed for fat metabolism effects, with limited clinical evidence

Multipurpose peptides:

• KPV — a tripeptide fragment of alpha-MSH with anti-inflammatory properties (distinct from the longevity research context where it is also studied)

These compounds are promoted for muscle growth, fat loss, recovery acceleration, and anti-inflammatory effects. Their receptor selectivity and relatively short half-lives are cited by proponents as safety advantages over traditional anabolic-androgenic steroids (AAS).

What the Evidence Actually Shows

The review’s central finding is a mismatch: the clinical evidence supporting peptide use in healthy, performance-seeking individuals is minimal. Most published studies examine these compounds in therapeutic contexts — GH deficiency, muscle wasting, specific metabolic disorders — under controlled dosing by physicians.

That is a fundamentally different situation from the protocols actually used in sport and bodybuilding, which typically involve:

• Supraphysiological doses — often far above therapeutic ranges
• Stacking — combining multiple peptides with each other, or with AAS, SARMs, and other compounds
• Self-administration — without medical supervision, laboratory monitoring, or standardized product quality

The clinical evidence for therapeutic doses, the review notes, does not reliably predict what happens with the self-administration protocols common in fitness communities.

The Risk Signals

The review documents several categories of concern for performance-focused use:

Cardiovascular Strain

GH secretagogues stimulate growth hormone and downstream IGF-1 production. Chronically elevated IGF-1 and GH levels are associated with:

• Cardiac hypertrophy (enlargement of the heart muscle)
• Increased cardiovascular risk over long-term exposure

The review notes this signal exists even with compounds marketed as “selective” — selectivity for the GH axis does not insulate the cardiovascular system from downstream effects.

Metabolic Effects

Elevated GH and IGF-1 levels can drive:

• Insulin resistance — counterintuitively, given that GH secretagogues are often used in weight management contexts
• Dyslipidemia — alterations in cholesterol and lipid profiles

These effects are dose-dependent and particularly relevant for protocols involving high doses or long cycles.

Psychiatric Instability

This is perhaps the least discussed risk. The review documents psychiatric effects — including mood instability, impulsivity, and in some cases more severe symptoms — associated with compounds affecting the GH-IGF-1 axis. The mechanisms are not fully understood, but the signal appears across multiple substances.

The Supply Chain Problem

For the review’s authors, the unregulated supply chain is the most immediate and practically significant risk. Peptides sold through online vendors and gray-market channels are:

• Frequently mislabeled — the compound listed on the label may not match what is in the vial
• Often improperly dosed — concentrations may vary significantly from stated values
• Potentially contaminated — with bacterial endotoxins, heavy metals, or other substances

This is not a theoretical concern. Third-party testing of commercially available peptides has repeatedly found quality failures. The injectable route of administration — the most common for GH secretagogues — makes contamination particularly dangerous.

WADA and Detection

The World Anti-Doping Agency has prohibited growth hormone secretagogues and fragments since 2008. As the peptide landscape has evolved, so has detection methodology — though the review notes that analytical challenges remain.

Peptides structurally similar to endogenous hormones can be difficult to distinguish from natural hormone fluctuations. Short half-lives mean the window for detection may be narrow. Sophisticated detection methods based on blood passport data (looking for systemic effects rather than direct compound detection) are increasingly being deployed.

For competitive athletes, the risk of suspension is real — and the combination of limited evidence for performance benefit and meaningful detection risk makes the cost-benefit calculation particularly unfavorable.

The Recreational Landscape

The review highlights an important gap: while elite sport gets the most regulatory attention, the largest population of peptide users is now recreational gym-goers and bodybuilders who are not competing under any anti-doping framework.

Anecdotal evidence and social media prevalence suggest growing uptake among people who may be significantly younger than the patient populations in most clinical studies. The review explicitly identifies this as a “critical gap” — robust prevalence data for recreational peptide use does not exist.

This matters because younger recreational users may assume that compounds studied in adult populations with GH deficiency or specific metabolic conditions are similarly safe for healthy, younger people seeking performance enhancement. That assumption is not supported by the evidence.

The Bottom Line

The review’s conclusion is measured but clear: peptides “represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks.” The authors explicitly classify peptide use in both competitive and recreational settings as “high-risk and ethically problematic” until longitudinal safety data is available.

For informed consumers, this translates to a few practical considerations:

• The “safer than steroids” framing does not mean safe — it means the risk profile is different, not absent
• The protocols actually used in performance contexts bear little resemblance to the clinical studies cited in their defense
• The supply chain risk is real and immediate, regardless of what the research eventually shows about the compounds themselves
• Consulting a physician before considering any of these compounds is not optional framing — it is a genuine prerequisite for informed decision-making

Source

Coutinho LFD, DE Oliveira Neves LF, Camilo RP. “A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.” Journal of Sports Medicine and Physical Fitness. March 25, 2026. PMID: 41880199 | DOI: 10.23736/S0022-4707.26.17773-1